ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
December 6, 2022
Ryan Allway December 6th, 2022 News, Top News – Preclinical and early clinical studies of MYMD-1®, an oral, small-molecule, selective TNF-α inhibitor, suggest future potential to disrupt the Rheumatoid Arthritis market – BALTIMORE, December 06, 2022–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing... Read more
MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
November 17, 2022
Ryan Allway November 17th, 2022 News, Top News – Preclinical and early clinical studies of MYMD-1®, an oral, small-molecule, selective TNF-α inhibitor accepted for presentation – BALTIMORE, November 17, 2022–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious... Read more
